2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness
Related Posts
Ma J, Lai CQ, Li XS, Wang M, Wang Z, Yao J, Guo X, Taylor KD, Lee S, Tracy RP, Peter D, Liu Y, Rotter[...]
Perez JS, Hudson H, Araneta J, Bedell B, Aikins AD, Dugas LR, Eid M, Eshac Y, Fariduddin M, Fariduddin M, Jong K, Kapwata T, Luke[...]
Lacasse Y, Maltais F, Casaburi R. The Potential of Chronic Hypoxia Biomarkers to Guide Home Oxygen Therapy Prescription in COPD. Respir Care. 2026 Jan;71(1):97-102. doi:[...]